Literature DB >> 7721638

Adjuvant radiation therapy for rectal carcinoma: predictors of outcome.

R J Myerson1, J M Michalski, M L King, E Birnbaum, J Fleshman, R Fry, I Kodner, D Lacey, M A Lockett.   

Abstract

PURPOSE: To review predictors of outcome, including sequencing of modalities and pretreatment findings for adjuvantly treated rectal cancer. METHODS AND MATERIALS: From 1975 through 1990, 307 patients with adenocarcinoma of the rectum underwent adjuvant radiation therapy. In 251 cases the radiation therapy was administered preoperatively, either 40-50 Gy (median dose 45 Gy) followed in 6-7 weeks by surgery (210 cases), or 20 Gy in five fractions immediately prior to surgery (41 cases). In 56 cases, patients were referred postoperatively for radiation (median dose 50 Gy). Adjuvant chemotherapy was never given concurrently with the preoperative radiation (RT), although 43 of the cases (including 14 of the preoperative RT cases) received postoperative chemotherapy.
RESULTS: Multivariate analysis (Cox model) indicated that significant predictors of better overall freedom from disease were preoperative rather than postoperative RT (p < 0.001), low surgical stage (p < 0.0001), specialist surgeon (p = 0.007), low or moderate histologic grade (p = 0.026), and proximal lesion (p = 0.033). The significant predictors for better local control included use of preoperative RT (p < 0.001), low or moderate grade (p = 0.001), and low surgical stage (p = 0.015). The 5-year local control and freedom from disease for the preoperative RT patients were 90% +/- 2% and 73% +/- 3%, respectively. The selected cases that received the short course of 20 Gy preoperatively did well. Although 24 out of 41 patients proved to have Astler Coller B2 or C disease, local control at last follow-up was 39 out of 41 (95%). A second multivariate analysis of pretreatment factors was performed on the preoperative RT cases. The significant factors for both local control and overall freedom from disease were noncircumferential vs. circumferential tumor, proximal vs. distal lesion, and background of the surgeon. Additional negative factors on univariate analysis (although not achieving independent significance on multivariate analysis) included the finding of near-obstructing lesions and elevated carcinoembryonic antigen (CEA). Grade > or = 3 sequelae occurred in 8% of cases (including 3% bowel obstruction). The only significant factor for complications was background of the surgeon (4% for colorectal specialists vs. 12% for nonspecialists, p = 0.015).
CONCLUSIONS: Significant factors for better tumor control included preoperative as opposed to postoperative RT and the experience of the surgeon. In selected cases, excellent results can be obtained with a short course of preoperative radiation. Concurrent chemotherapy need not be given routinely with preoperative radiation. Subgroups of preoperative RT cases at risk for distant metastases (who might benefit from postoperative chemotherapy), and at high risk for local failure (for whom concurrent preoperative chemotherapy and radiation might be considered), are identified.

Entities:  

Mesh:

Year:  1995        PMID: 7721638     DOI: 10.1016/0360-3016(94)00493-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Preoperative chemoradiotherapy in the management of localized rectal cancer: the new standard.

Authors:  Theodore S Hong; Lisa A Kachnic
Journal:  Gastrointest Cancer Res       Date:  2007-03

Review 2.  Sphincter preservation in rectal cancer.

Authors:  C G Willett
Journal:  Curr Treat Options Oncol       Date:  2000-12

3.  Adjuvant chemoradiation for localized rectal cancer: current trends and future directions.

Authors:  Lisa A Kachnic
Journal:  Gastrointest Cancer Res       Date:  2007

Review 4.  [Adjuvant and neoadjuvant therapy of rectal carcinoma. The current status].

Authors:  C Rödel; W Hohenberger; R Sauer
Journal:  Strahlenther Onkol       Date:  1998-10       Impact factor: 3.621

5.  WRAP53 is an independent prognostic factor in rectal cancer- a study of Swedish clinical trial of preoperative radiotherapy in rectal cancer patients.

Authors:  Hong Zhang; Da-Wei Wang; Gunnar Adell; Xiao-Feng Sun
Journal:  BMC Cancer       Date:  2012-07-17       Impact factor: 4.430

6.  Which Definition of Upper Rectal Cancer Is Optimal in Selecting Stage II or III Rectal Cancer Patients to Avoid Postoperative Adjuvant Radiation?

Authors:  Xian Hua Gao; Bai Zhi Zhai; Juan Li; Jean Luc Tshibangu Kabemba; Hai Feng Gong; Chen Guang Bai; Ming Lu Liu; Shao Ting Zhang; Fu Shen; Lian Jie Liu; Wei Zhang
Journal:  Front Oncol       Date:  2021-02-12       Impact factor: 6.244

7.  Recognition of Anterior Peritoneal Reflections and Their Relationship With Rectal Tumors Using Rectal Magnetic Resonance Imaging.

Authors:  Sun Yiqun; Tong Tong; Liu Fangqi; Cai Sanjun; Xin Chao; Gu Yajia; Xu Ye
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.